Descrizione del progetto
Progredire nell’immunoterapia cellulare con i gemelli virtuali
Il progetto CERTAINTY, finanziato dall’UE, si dedica al miglioramento del trattamento del cancro attraverso lo sviluppo di gemelli virtuali per le terapie a base di cellule T esprimenti un recettore chimerico per antigene (CAR-T), utilizzando le cellule dei pazienti. Nato dall’esigenza di rendere questa terapia innovativa più accessibile e personalizzata, CERTAINTY utilizzerà sofisticati modelli computazionali e dati reali dei pazienti per creare repliche digitali che rispecchino le condizioni di salute individuali. Questi gemelli virtuali potrebbero perfezionare le strategie di trattamento per tumori come il mieloma multiplo e sono progettati per prevedere la risposta dei pazienti alla terapia. Integrato nel programma «Europa Digitale», il progetto prevede di adattare la sua tecnologia ad altre terapie cellulari. Unendo tecnologie all’avanguardia e dati clinici, CERTAINTY supporterà trattamenti maggiormente personalizzati e potenzialmente efficaci, rendendo più accessibili le terapie avanzate e migliorando gli esiti per la salute grazie a un processo decisionale informato.
Obiettivo
"This project aims to create a multi-scale patient-specific human virtual twin for patients who are eligible for CAR T cell therapy, which can be extended to cellular immunotherapies in general. The virtual twin will be fully integrated into the ecosystem under the Digital Europe Programme and will be available as a research-use-only prototype in relevant application environments with technology readiness level 6. The virtual twin will support decision-making throughout the patient's journey, from diagnosis to pre-treatments, cellular immunotherapy, and late patient monitoring. This will enable patients and health experts to identify the most effective course of therapy.
The virtual twin for cellular immunotherapies will take multi-scale modelling to the next level by providing methodological concepts for integrating ""living drugs"" such as CAR T cells into the human virtual twin ecosystem.
To achieve this goal, the project builds on existing data models for hematological malignancies and multiple myeloma (MM) to create a virtual twin for CAR T cell therapy for MM patients. The implementation process follows software development principles for software as medical devices, ensuring the exploitation of the research-use-only prototype. Patient's, SSH, gender differences, and other stakeholders' perspectives are fully integrated into the design, specification, and implementation process.
Throughout the implementation process, a modular software architecture and extensible ontologies/terminologies are utilized, making the reference model easily transferable to other indications that can be treated with CAR T cell therapy or other cellular immunotherapies. Overall, the CERTAINTY virtual twin will provide decision support for patients and health experts, improving the effectiveness of cellular immunotherapies and advancing precision medicine."
Campo scientifico
- natural sciencescomputer and information sciencessoftwaresoftware development
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencesbiological sciencesecologyecosystems
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesmedical biotechnologycells technologies
Parole chiave
Programma(i)
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
80686 Munchen
Germania